The White House has rolled out TrumpRx, a new government website that promises sharply lower prices on dozens of prescription drugs — a move the White House is hailing as historic, though experts warn its reach may be limited.
Drugs that once cost more than $1,000 a month are now listed for a few hundred dollars or less on TrumpRx.
The portal currently lists 43 brand-name drugs, with advertised discounts ranging from 50% to more than 90%.
The biggest headliners are weight-loss and diabetes medications from Novo Nordisk and Eli Lilly, including Wegovy pills and pens discounted as much as 89%, Ozempic pens marked down up to 81%, and Lilly’s Zepbound offered at about 72% off.
Insulin Lispro is listed starting at $25, a price the administration has repeatedly highlighted as a benchmark for affordability.
The drugs also include fertility treatments from EMD Serono — such as Gonal-F, Ovidrel and Cetrotide — alongside diabetes drugs like Farxiga and Xigduo XR and thyroid medications including Levoxyl and Cytomel.
TrumpRx lists a mix of respiratory, autoimmune, hormone and mental health drugs, too.
Many of the medications are older brand-name products — some with generic alternatives already on the market, which is why experts believe that TrumpRx’s sharpest savings are likely to benefit patients paying out of pocket rather than the majority of Americans with insurance coverage.
The website does not sell drugs directly.
Instead, it functions as a clearinghouse that steers patients to manufacturer-sponsored discount programs, coupon codes and participating pharmacies where medications are purchased with cash rather than insurance.
Because the transactions bypass insurers and pharmacy benefit managers, purchases made through TrumpRx typically do not count toward deductibles or annual out-of-pocket limits — a key reason experts say the program is best suited for uninsured or cash-pay patients.
Darren Covington, executive vice president of the Indiana Pharmacy Association, described the early reaction as mixed.
“I talked to individuals, you know, some are very excited about it and some are skeptical of it,” he told Scripps News.
“We know that when patients are able to afford and access their medications, that leads to healthier outcomes. So we’re hopeful, yes.”
Academic health policy experts warned that the benefits are likely overstated for most Americans.
Sean Sullivan, a professor of health economics and policy at the University of Washington, wrote in STAT News: “TrumpRx won’t help most Americans because it is designed for cash-paying, uninsured patients rather than the roughly 85% of Americans with prescription drug insurance coverage.”
“For most Americans, this initiative represents not a solution to our prescription drug price dilemma, but rather a distraction from it.”
